DRMA

Dermata Therapeutics, Inc. NASDAQ Listed Aug 13, 2021

Healthcare ·Biotechnology ·US · dermatarx.com

$1.30

Mkt Cap $886,024

52w Low $1.10 2.7% of range 52w High $8.64

50d MA $1.28 200d MA $3.19

P/E (TTM) -0.2x

EV/EBITDA 967.4x

P/B 0.0x

Debt/Equity 0.0x

ROE -121.4%

P/FCF -0.0x

RSI (14) —

ATR (14) —

Beta 0.50

50d MA $1.28

200d MA $3.19

Avg Volume 1.5M

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

CIK (SEC)

1853816

Phone

858 800 2543

3525 Del Mar Heights Road · San Diego, CA 92130 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 26, 2026	AMC	-1.54	-1.52	+1.3%	1.37	-0.7%	-13.9%	-3.4%	+6.1%	-0.8%	+7.5%	—
Nov 14, 2025	AMC	-1.59	-1.65	-3.8%	3.07	+2.0%	-7.5%	-6.0%	-8.6%	+2.5%	+4.0%	—
Aug 13, 2025	AMC	-2.90	-1.66	+42.8%	6.45	-1.4%	-9.9%	+2.9%	-1.0%	-4.7%	-4.1%	—
May 14, 2025	AMC	-0.45	-4.50	-900.0%	0.78	-2.4%	+1.9%	-0.4%	+4.9%	-2.7%	-4.7%	—
Mar 17, 2025	AMC	-1.50	-3.15	-110.0%	1.17	+0.0%	+2.6%	+1.7%	-3.3%	+5.1%	+4.8%	—
Nov 13, 2024	AMC	-2.64	-2.04	+22.7%	1.23	+0.0%	-3.3%	-5.9%	-3.6%	+0.0%	+7.4%	—
Aug 7, 2024	AMC	-3.79	-4.18	-10.3%	2.33	-7.7%	+12.4%	-6.1%	-7.7%	-2.6%	+2.3%	—
May 15, 2024	AMC	-5.40	-7.05	-30.6%	4.95	-2.0%	+5.1%	-19.2%	-10.5%	-9.0%	+5.8%	—
Mar 21, 2024	AMC	-0.78	-3.15	-303.8%	6.00	+8.8%	+3.8%	+0.0%	-2.7%	-2.6%	+4.4%	—
Nov 9, 2023	AMC	-0.63	-8.10	-1185.7%	11.73	-4.9%	-7.8%	-7.1%	-4.1%	+1.5%	+6.7%	—
Aug 10, 2023	AMC	-0.92	-9.45	-927.2%	17.40	-0.9%	-2.6%	+2.7%	+1.7%	+6.8%	-3.2%	—
May 11, 2023	AMC	-2.65	-34.03	-1184.2%	28.95	+71.0%	+35.2%	-1.1%	+0.8%	+3.5%	-8.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 21	Maxim Group	Maintains	Buy → Buy	—	$5.41	$5.24	-3.1%	-1.5%	+2.8%	+6.4%	-5.7%	-3.8%
May 21	Maxim Group	Maintains	Buy → Buy	—	$0.81	$0.82	+1.5%	-4.7%	-0.3%	-3.1%	+0.8%	-2.7%
Aug 21	Maxim Group	Maintains	Buy → Buy	—	$2.02	$2.03	+0.5%	-4.0%	-5.2%	-2.7%	-5.6%	+3.6%
Mar 23	Maxim Group	Maintains	Buy → Buy	—	$20.10	$20.85	+3.7%	+25.4%	-8.3%	-9.7%	-10.1%	+8.0%

Data updated apr 25, 2026 5:46am · Source: massive.com